The world's scientific and social network for malaria professionals

Poll

US PMI and PATH should revise 30 million $ contract and include leading African malaria institutions as full partners (see: https://www.nature.com/articles/s41591-021-01307-8)

Yes

95%

Total votes: 58

Older polls

malaria vaccine

Natural selection and genetic diversity of domain I of Plasmodium falciparum apical membrane antigen-1 on Bioko Island

Tags:

Natural selection and genetic diversity, apical membrane antigen-1

Author(s):

Ya-Nan Wang, Min Lin, Hai-Bin Chen, et al.

Reference:

Malaria Journal 2019 18:317, 18 September 2019

Plasmodium falciparum apical membrane antigen-1 (PfAMA-1) is a promising candidate antigen for a blood-stage malaria vaccine. However, antigenic variation and diversity of PfAMA-1 are still major problems to design a universal malaria vaccine based on this antigen, especially against domain I (DI). Detail understanding of the PfAMA-1 gene polymorphism can provide useful information on this potential vaccine component. Here, general characteristics of genetic structure and the effect of natural selection of DIs among Bioko P. falciparum isolates were analysed.

Country:

Bioko Island

Medical Condition:

Plasmodium falciparum

Medical Treatment:

malaria vaccine

Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation

Tags:

plasmodium falciparum

Author(s):

Bart W. Faber, Stephan Hellwig, Edmond J. Remarque, et al.

Reference:

PLoS ONE 11(10): e0164053

Plasmodium falciparum apical membrane antigen 1 (PfAMA1) is a leading asexual blood stage vaccine candidate for malaria.

Medical Treatment:

malaria vaccine

The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine

Tags:

plasmodium falciparum

Author(s):

Morten A. Nielsen, Mafalda Resende, Ali Salanti, et al.

Reference:

PLoS ONE 10(9): e0135406

The disease caused by Plasmodium falciparum (Pf) involves different clinical manifestations that, cumulatively, kill hundreds of thousands every year.

Medical Treatment:

malaria vaccine

Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum

Tags:

malaria

Author(s):

Li T, Eappen AG, Richman AM, Billingsley PF, Abebe Y, Li M, Padilla D, Rodriguez-Barraquer I, Sim B, Hoffman SL

Reference:

Malaria Journal 2015, 14 :150 (9 April 2015)

These results demonstrate a robust capacity to perform the SMFA in a medium-to-high throughput format, suitable for assessing large numbers of experimental samples of candidate antibodies or drugs.

Medical Treatment:

malaria vaccine

Calibration of an intrahost malaria model and parameter ensemble evaluation of a pre-erythrocytic vaccine

Tags:

malaria

Author(s):

Kevin A McCarthy, Edward A Wenger, Grace H Huynh, Philip A Eckhoff

Reference:

Malaria Journal 2015, 14:6 (7 January 2015)

Roll-out of routine immunization with pre-erythrocytic malaria vaccines can provide substantial burden reduction across a range of transmission conditions typical to many regions in Africa.

Continent:

Africa

Medical Treatment:

malaria vaccine

Acceptance of a malaria vaccine by caregivers of sick children in Kenya

Tags:

malaria

Author(s):

Ojakaa DI, Jarvis JD, Matilu MI, Thiam S

Reference:

Malaria Journal 2014, 13 :172 (5 May 2014)

Results from this study indicate a need for targeted messages and education on a malaria vaccine, particularly for residents of regions where acceptance is low, older caregivers, and those with low literacy and school-attendance levels.

Country:

Kenya

Medical Treatment:

malaria vaccine

NOT Open Access | Tricomponent Complex Loaded with a Mosquito-Stage Antigen of the Malaria Parasite Induces Potent Transmission-Blocking Immunity

Tags:

malaria

Author(s):

Takeshi Arakawa, Takafumi Tsuboi, Jetsumon Sattabongkot, Kozue Sakao, Motomi Torii, and Takeshi Miyata

Reference:

Clin Vaccine Immunol April 2014 vol. 21 no. 4 561-569

The development of malaria vaccines is challenging, partly because the immunogenicity of recombinant malaria parasite antigens is low.

Medical Treatment:

malaria vaccine

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

Author(s):

Abdulla S, Salim N, Tanner M, et al.

Reference:

Malaria Journal 2013, 12:11 (8 January 2013)

Safety, immunogenicity and efficacy of the RTS,S/AS02D vaccine candidate when integrated into a standard EPI schedule for infants have been reported over a nine-month surveillance period. This paper describes results following 20 months of follow up.

Person:

infant

Organization:

World Health Organization

Medical Treatment:

malaria vaccine

Not Open Access | Review: Development of a virosomal malaria vaccine candidate: from synthetic peptide design to clinical concept validation

Author(s):

Gerd Pluschke & Marco Tamborrini

Reference:

Future Virology, August 2012, Vol. 7, No. 8, Pages 779-790

MalariaWorld In this review, we summarize and discuss a strategy to develop synthetic peptidomimetics of key malaria target antigens for inclusion in a multivalent malaria subunit vaccine based on immunopotentiating reconstituted influenza virosomes.